Skip to content
value.today

Othera Pharmaceuticals, Inc.

Formerly OTHERA PHARMACEUTICALS INC

Total raised
$11 M
1 round on record
Latest round
$11 M
Oct 2008
First round on record
Oct 2008
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Othera Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2008$11 MNo. 1$10 to $50 million

Othera Pharmaceuticals, Inc.: Raise no. 1, Oct 2008

Investors in this round

26 investors had bought by the notice of Aug 4, 2009: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered; $0 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$350,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Pennsylvania

People named in the notice

  • David S. Joseph · Executive Officer, Director
  • Brian G. Murphy · Director
  • Hans Mueller · Director
  • Katherine Crothall · Director
  • Rami Elghandour · Director
  • Thomas R. Morse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Further proceeds include exercise price of Warrants to be issued at a later date, which exercise price is not yet determinable, and Warrants to purchase shares of Series C Convertible Preferred Stock at an aggregate exercise price of $1,769,994.”

Signed by Philip Heifetz, Vice President. Source: SEC Form D and 1 amendment, newest notice filed Aug 4, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Othera Pharmaceuticals, Inc. had no revenue when it filed its newest notice of a funding round (Aug 2009).

    SEC Form D (revenue range) · Aug 2009

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2009

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Othera Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 26 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Othera Pharmaceuticals, Inc.
NameRoleNamed in
David S. JosephExecutive officerAug 2009
Brian G. MurphyDirectorAug 2009
David S. JosephDirectorAug 2009
Hans MuellerDirectorAug 2009
Katherine CrothallDirectorAug 2009
Rami ElghandourDirectorAug 2009
Thomas R. MorseDirectorAug 2009